News & Events
13.05.2020
NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine
31.05.2019
Neovii & Mundipharma Confirm In-licensing Agreement
15.09.2017
Neovii Pharmaceuticals AG announces new CEO
26.07.2017
Neovii completes marketing authorisation withdrawal of Removab® in the European Union
14.09.2016
Neovii Pharmaceuticals AG licenses worldwide (excluding U.S. & Japan) developmental and commercialization rights for ARCALYST® (rilonacept) from Regeneron for the treatment of periodic fever syndromes
14.01.2016
European study in patients with acute leukemia shows the inclusion of Grafalon® (anti T-lymphocyte immunoglobulin) in a conditioning regimen before stem cell transplantation from HLA-identical siblings results in a significantly lower incidence of chronic GvHD.
